India patent law case finally hits court
If successful, the move would have a devastating impact on access to essential medicines across the developing world, according to international humanitarian medical organisation Médecins Sans Frontières (MSF), which relies on affordable generic drugs produced in India to carry out its work in 68 countries.
‘For six years, Novartis has been trying to browbeat India into changing a part of its patent law that protects people’s access to affordable medicines, not corporate profits’, said Leena Menghaney, Manager of MSF’s Access Campaign in India. ‘The current system in India was designed to prevent drug companies from extending patent monopolies with additional patents on the same medicine.’
Novartis has been engaged in a legal battle over a part of India’s patent law (known as Section 3d) which says that a new form of a known medicine can only be patented if it shows significantly improved therapeutic efficacy over existing compounds; this is a provision to stop the common industry practice of extending, or ‘evergreening,’ their patent monopolies for routine modifications of known compounds.
Section 3d, which is in line with international trade rules, formed the basis for Novartis not being granted a patent for its cancer drug imatinib mesylate (marketed as Gleevec) in 2006. Novartis’ patent application was on a new form of the imatinib molecule already described several years previously in patents in the US and other developed countries.
‘We’ve already seen the benefits of public health safeguards in India’s patent law in practice’, said Menghaney. ‘Thanks to India’s strict law, patent applications on paediatric versions and fixed-dose combinations of drugs used to treat HIV have been rejected. These are the very medicines that need generic competition to be affordable.’
The ramifications of a Novartis win would be global, with India in the future being forced to grant far more patents than it currently does. This in turn would greatly restrict the kind of generic competition that has, for example, been instrumental in bringing the price of HIV medicines down by 99 per cent since 2000, and made the scale-up of HIV treatment to eight million people in developing countries possible.
‘Because India is the developing world’s pharmacy, the consequences of this case stretch far beyond the country’s borders,’ said Dr. Manica Balasegaram, Executive Director of MSF’s Access Campaign. ‘Novartis’s legal actions are a direct threat to the lifeline for millions of people in developing countries.’
For further info & to arrange interviews, please contact:
Kate Ribet, Communications Officer, MSF SA
kate.ribet@joburg.msf.org or 079 872 2950 | www.msf.org.za
Author
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
View all posts
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
India patent law case finally hits court
by Health-e News, Health-e News
September 11, 2012